Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Acura Pharmaceuticals Sues Ranbaxy Over Painkiller Drug

April 30 (Bloomberg) -- Acura Pharmaceuticals Inc., whose technology helps deter drug abuse, sued Ranbaxy Laboratories Ltd., India’s largest drugmaker, over its plan to market a generic version of the painkiller Oxecta.

Acura, based in Palatine, Illinois, claimed New Delhi-based Ranbaxy wrongly plans to market a copy of the short-acting oxycodone pill before Acura’s patent expires in 2025, according to papers filed yesterday in federal court in Delaware.

“Acura will be substantially and irreparably harmed by Ranbaxy’s infringing activities” unless stopped by a judge, according to the complaint.

Ranbaxy reported about $2.2 billion in sales for fiscal 2012. Acura listed about $20 million in fiscal 2011 sales and a net loss last year, according to data compiled by Bloomberg.

Charles M. Caprariello, a U.S. spokesman for Ranbaxy, didn’t immediately return a call seeking comment on the lawsuit.

The case is Acura v. Ranbaxy, 13-cv-00750, U.S. District Court, District of Delaware (Wilmington).

To see the patent in the lawsuit, click: 7,510,726.

To contact the reporter on this story: Phil Milford at pmilford@bloomberg.net.

To contact the editor responsible for this story: Michael Hytha at mhytha@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.